Pfizer Inc (MIL:1PFE)
€ 24.62 -0.33 (-1.32%) Market Cap: 140.00 Bil Enterprise Value: 193.63 Bil PE Ratio: 34.77 PB Ratio: 1.58 GF Score: 59/100

Pfizer Inc at Goldman Sachs Global Healthcare Conference Transcript

Jun 15, 2022 / 03:40PM GMT
Chris Shibutani;
Goldman Sachs Group, Inc., Research Division - Research Analyst

Welcome to our session here at the Goldman Sachs Healthcare Conference. I'll have to let Keira know that we observe that 8-hour, 5-minute time difference between here and London. We're super pleased here to have Pfizer join us. My name is Chris Shibutani. I'm a member of the Goldman Sachs research team covering pharmaceuticals and biotechnology. Pfizer here is strongly represented by the tour de force the R&D group, Mikael Dolsten, who's been heading up that effort for many years now. And the newest member of the team, Dr. William Pao, welcome.

And I think it will be as an introduction. I think many of us are familiar with Mikael, but give you a chance to sort of tell us a little bit about your story, your background. I know you're coming over from pRED at Roche, a little bit of shift in sort of like the stage of things that you're looking at. Give us a sense for what your background and what your mission is, why you're the right guy for Albert to tap you as he continues to shape the C-suite?

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot